RxDoctor Payments Data

David Lillie, MD

Urology · Kenmore, NYNPI 1952306201

Payments from drug & device makers

$3,382in general payments, 2019–2025

Across 143 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$981
  • Johnson & Johnson$667
  • Pfizer$537
  • AbbVie$140
  • Calyxo, Inc.$129
  • Abbott$120
  • plus $809 from 16 others

What the payments were for

  • Food & beverage$3,18494%
  • Education$1986%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,382 in reported general payments places this provider in the 50th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$77,655
Medicare patients
358
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide54$670,221
MyrbetriqMirabegron197$129,004
GemtesaVibegron74$74,316
Tamsulosin Hcl2,585$57,051
EligardLeuprolide Acetate23$28,923
Finasteride1,755$28,871
Testosterone78$16,893
Trospium Chloride ErTrospium Chloride149$16,889
ElmironPentosan Polysulfate Sodium11$10,540
Mirabegron ErMirabegron22$7,570
Tolterodine Tartrate ErTolterodine Tartrate54$5,484
Trospium Chloride117$5,187
Oxybutynin Chloride ErOxybutynin Chloride158$3,569
NitrofurantoinNitrofurantoin Macrocrystal126$3,214
Doxazosin Mesylate221$3,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$981$799,226251 claims
Sumitomo Pharma America, Inc.Gemtesa$44$74,31674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 952 urology providers in New York.

Other urology in Kenmore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →